Screener
Tarsus Pharmaceuticals, Inc. TARS Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization?
- Tarsus Pharmaceuticals, Inc. (TARS) reported finite-lived intangible assets, accumulated amortization of $2.12M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization increased by 83.3% year-over-year, from $1.15M to $2.12M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization?
- Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization has grown at a 304.2% compound annual growth rate (CAGR), from $100K to $1.63M.
- What does finite-lived intangible assets, accumulated amortization mean?
- Finite-Lived Intangible Assets, Accumulated Amortization
Ask your AI about Tarsus Pharmaceuticals, Inc.'s finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude